Shree Pacetronix Limited is a pioneering Indian medical technology company that has spent over **30 years** specializing in the design, manufacture, and distribution of cardiac rhythm management (CRM) devices. As one of the few indigenous players in a sector traditionally dominated by global multi-national corporations (MNCs), the company has successfully achieved over **1,00,000 implants** globally. The company operates in a high-entry-barrier industry, maintaining rigorous quality certifications including **ICMED 13485**, **ISO 13485**, and **ISO 9001**. --- ### **Core Product Portfolio & Clinical Applications** The company operates under a single primary business segment: **"Life Saving Devices."** Its product line addresses critical cardiac conditions such as arrhythmias, heart failure, and sinus node dysfunction. | Product Category | Clinical Application | Technical Function | | :--- | :--- | :--- | | **Single Chamber Pacemaker** | Atrial fibrillation / Bradycardia | Stimulates the lower right chamber (ventricle) of the heart. | | **Dual Chamber Pacemaker** | AV Block / Sinus Node Dysfunction | Coordinates electrical signals between the upper (atria) and lower chambers. | | **Biventricular Pacemaker (CRT)** | Advanced Heart Failure | Stimulates both lower chambers simultaneously to improve cardiac output. | | **Ancillary Equipment** | Surgical Support | Includes **Pacing Leads** and **Pacing System Analyzers** for implant calibration. | --- ### **Strategic R&D and Innovation Roadmap** To compete in a global market valued at **USD 4.68 billion (2024)**, Shree Pacetronix is pivoting toward high-growth technological advancements: * **Miniaturization:** Transitioning toward **compact, minimally invasive** models to reduce surgical complications and recovery times. * **Device Longevity:** Engineering **longer-lasting batteries** to minimize the frequency of replacement surgeries. * **Digital Integration:** Developing **Bluetooth connectivity** and **advanced remote monitoring** capabilities for real-time patient data tracking. * **Safety Enhancements:** Researching **MRI-safe (MRI-compatible)** designs and **next-generation leadless** pacemakers to eliminate lead-related complications. --- ### **Operational Structure & Manufacturing Footprint** The company utilizes a vertically integrated model to control quality and distribution. * **Manufacturing Hub:** The primary facility is located in **Pithampur, Madhya Pradesh**. This site handles the high-precision assembly of implantable devices. * **Subsidiary Operations:** **Shree Coratomic Limited** (99.91% owned) serves as the trading and distribution arm, based in **Indore**. * **National Reach:** Maintains a service and distribution presence in major metros, including **Bangalore** and **Kolkata**, to support nationwide hospital networks. --- ### **Financial Performance & Capital Structure** Shree Pacetronix has maintained a stable financial trajectory with a focus on improving profitability through operational efficiency. **Key Financial Metrics (Standalone):** * **Revenue (FY 2023-24):** **₹22.04 crore** (up from **₹20.19 crore** in FY 2022-23). * **Profit After Tax (PAT):** **₹3.36 crore** (FY 2023-24). * **Return on Net Worth (RoNW):** **28.83%** (FY 2024-25). * **Short-term Borrowings:** **₹3.75 crore** (as of March 2024), primarily for working capital. **Capital Infusion & Ownership Change (2025-2026):** The company is undergoing a significant consolidation of promoter control to fund future growth: * **Preferential Allotment:** Issuance of **75,150 equity shares** and **2,25,450 warrants** to Mr. Akash Sethi at **₹81 per unit**, raising approximately **₹2.43 crore**. * **Open Offer:** An offer to public shareholders to acquire up to **9,75,000 shares** at **₹100 per share** (Total consideration: **₹9.75 crore**). * **Post-Transaction Holding:** Promoter/PAC shareholding is projected to increase from **24.25%** to **55.09%** of the fully diluted capital. --- ### **Market Dynamics & Growth Catalysts** The Indian pacemaker market is projected to grow from **USD 220.75 million in 2024** to **USD 299.07 million by 2030** (**CAGR of 5.15%**). * **"Make in India" Advantage:** The company is well-positioned to benefit from the **Production Linked Incentive (PLI)** Scheme and the **Promotion of Medical Device Parks Scheme**, which favor indigenous manufacturing over imports. * **Demographic Tailwinds:** An aging population and rising cardiovascular disease incidence in **Tier-2 and Tier-3** cities provide a massive untapped patient base. * **Import Substitution:** As the Indian healthcare market targets **$320 billion by FY 2028**, Shree Pacetronix aims to capture market share from expensive foreign brands by offering cost-effective, high-quality alternatives. --- ### **Risk Factors & Mitigation Challenges** **1. Audit & Financial Risks:** * **Qualified Opinions:** Auditors flagged a lack of formal impairment testing for an **₹80.00 lakh** investment in a suspended **Cochlear Implant Project**. * **Employee Benefits:** Non-compliance with **Ind AS 19** regarding actuarial valuations for gratuity obligations. * **Margin Pressure:** Reported profits were recently deemed "inadequate" under the Companies Act for certain director remuneration thresholds. **2. Operational & Industry Risks:** * **Technological Obsolescence:** The rapid shift toward **leadless** and **AI-enabled** devices requires heavy R&D spending. * **Supply Chain:** High dependence on global suppliers for specialized electronic components makes the company vulnerable to shipping delays and currency fluctuations. * **Security:** Recent incidents of theft and vandalism at industrial sites (Oct 2025) have resulted in inventory losses and highlighted infrastructure vulnerabilities. **3. Regulatory & Transactional Risks:** * **Compliance:** Lengthy clinical trial periods and stringent **CDSCO/FDA** approval processes can delay product launches. * **Open Offer Contingencies:** The ongoing change in control is subject to **BSE 'in-principle' approvals** and statutory clearances; any delay could impact the company's strategic timeline. --- ### **Corporate Governance & Leadership** The Board is structured to balance executive experience with independent oversight (**60% Independent Directors**). * **Managing Director:** **Mr. Atul Kumar Sethi** (Re-appointed through **November 2028**). * **Joint Managing Director:** **Mr. Akash Sethi** (Re-appointed through **August 2027**). * **Asset Protection:** Acquirers have committed to a **2-year moratorium** on alienating material assets of the company post-Open Offer, ensuring operational continuity.